Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Cell Reports|October 19, 2017
UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibitionTeresa Ezponda, Daphné Dupéré-Richer, Christine M Will, et al.
The Lancet. Oncology|January 18, 2018
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b studyCourtney D DiNardo, Keith W Pratz, Anthony Letai, et al.
Plos Genetics|September 5, 2014
Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylationRelja Popovic, Eva Martinez-Garcia, Eugenia G Giannopoulou, et al.
Blood Advances|January 30, 2024
Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemiaStephan Stilgenbauer, Eugen Tausch, Andrew W Roberts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2019
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II StudyAndrew H Wei, Stephen A Strickland, Jing-Zhou Hou, et al.
Blood|February 26, 2025
The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLLArnon P Kater, Rosemary Anne Harrup, Thomas J Kipps, et al.
In Vivo (Athens, Greece)|June 23, 2022
Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AMLDaniel H Albert, Neal C Goodwin, Angela M Davies, et al.
The Lancet. Oncology|March 11, 2024
Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trialArnon P Kater, Önder Arslan, Fatih Demirkan, et al.
Blood Advances|February 24, 2026
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapyAndrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
Blood Advances|November 21, 2025
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapyAndrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
Pageof 4